Voest EE - Search Results

1

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH. Boss DS, et al. Among authors: voest ee. Ann Oncol. 2011 Feb;22(2):431-7. doi: 10.1093/annonc/mdq344. Epub 2010 Oct 5. Ann Oncol. 2011. PMID: 20924078 Free article. Clinical Trial.

2

Clinical research on antiangiogenic therapy.

Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE. Kuiper RA, et al. Among authors: voest ee. Pharmacol Res. 1998 Jan;37(1):1-16. doi: 10.1006/phrs.1997.0268. Pharmacol Res. 1998. PMID: 9503474 Review.

3

Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.

Crul M, Beerepoot LV, Stokvis E, Vermaat JS, Rosing H, Beijnen JH, Voest EE, Schellens JH. Crul M, et al. Among authors: voest ee. Cancer Chemother Pharmacol. 2002 Dec;50(6):473-8. doi: 10.1007/s00280-002-0515-6. Epub 2002 Oct 25. Cancer Chemother Pharmacol. 2002. PMID: 12451474 Clinical Trial.

4

[The clinical perspective of angiogenesis inhibitors].

Radema SA, Witteveen PO, Gebbink MB, Voest EE. Radema SA, et al. Among authors: voest ee. Ned Tijdschr Geneeskd. 2003 Aug 30;147(35):1675-80. Ned Tijdschr Geneeskd. 2003. PMID: 14513538 Review. Dutch.

5

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Beerepoot LV, et al. Among authors: voest ee. Ann Oncol. 2004 Jan;15(1):139-45. doi: 10.1093/annonc/mdh017. Ann Oncol. 2004. PMID: 14679134 Free article.

6

Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.

Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, Voest EE. Bluyssen HA, et al. Among authors: voest ee. FEBS Lett. 2004 Jan 2;556(1-3):137-42. doi: 10.1016/s0014-5793(03)01392-9. FEBS Lett. 2004. PMID: 14706840 Free article.

7

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

Kerbusch T, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH. Kerbusch T, et al. Among authors: voest ee. Br J Cancer. 2004 Jun 14;90(12):2268-77. doi: 10.1038/sj.bjc.6601861. Br J Cancer. 2004. PMID: 15150579 Free PMC article. Clinical Trial.

8

The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery.

Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE. Lolkema MP, et al. Among authors: voest ee. Exp Cell Res. 2004 Dec 10;301(2):139-46. doi: 10.1016/j.yexcr.2004.07.016. Exp Cell Res. 2004. PMID: 15530850

9

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.

Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M. Lolkema MP, et al. Among authors: voest ee. J Biol Chem. 2005 Jun 10;280(23):22205-11. doi: 10.1074/jbc.M503220200. Epub 2005 Apr 11. J Biol Chem. 2005. PMID: 15824109 Free article.

10

Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.

Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG. Nieboer P, et al. Among authors: voest ee. J Clin Oncol. 2005 Nov 20;23(33):8296-304. doi: 10.1200/JCO.2005.10.167. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219926 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

362 results

Search Page